< Back to previous page
Researcher
Anne Marie Hausman
- Disciplines:Medical imaging and therapy, Other paramedical sciences, Genetics, Systems biology, Molecular and cell biology
Affiliations
- Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Sep 2004
Publications
1 - 10 of 13
- Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (vol 13, 77, 2021)(2021)
Authors: Julia Stomper, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Gabriele Ihorst, Nadja Blagitko-Dorfs, Gabriele Greve, Dennis Zimmer, Uwe Platzbecker, Anne Marie Hausman, et al.
- Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia(2020)
Authors: Anne Marie Hausman
Pages: 1551 - 1560 - Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype(2019)
Authors: Anne Marie Hausman
Pages: 1168 - 1175 - Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials(2018)
Authors: Anne Marie Hausman
Pages: 1785 - 1795 - Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial(2016)
Authors: Anne Marie Hausman
Pages: 972 - 979 - Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group(2016)
Authors: Anne Marie Hausman
Pages: 191 - 199 - High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial(2014)
Authors: Anne Marie Hausman
Pages: 219 - 228 - Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine(2011)
Authors: Anne Marie Hausman
Pages: 1119 - 1120 - A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy(2011)
Authors: Anne Marie Hausman
Pages: 393 - 401 - Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group(2011)
Authors: Anne Marie Hausman
Pages: 1987 - 1996